Lilly(Eli) & Company
NYSE: LLY
$903.58
+$7.99 (+0.9%)
Closing Price on October 29, 2024
LLY Articles
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, Beyond Meat, Biogen, Eli Lilly, Levi Strauss, Nvidia, Pfizer, Plug Power, Raytheon, Square and Wayfair.
Published:
Here are six health care stocks that appear to be specific winners based on a mixed Congress, regardless of which presidential candidate is declared the winner.
Published:
BofA Securities has released its top ideas for the rest of 2021. Here are eight top long ideas and two potential shorts for more aggressive investors.
Published:
Last Updated:
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Caterpillar, Corning, DexCom, Enphase Energy, First Solar, Invesco, 3M, Microsoft, Pfizer and Wynn Resorts.
Published:
Eli Lilly shares made a handy gain on Wednesday after the company announced an update to its SARS-CoV-2 neutralizing antibody programs.
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
Published:
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
Published:
Thursday's top analyst upgrades and downgrades included AGCO, Ambarella, Bank of America, Beyond Meat, Chipotle Mexican Grill, Costco Wholesale, CrowdStrike, Eli Lilly, JPMorgan, MongoDB, SmartSheet...
Published:
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Published:
These are five of the best stocks in a sector that has been humming along in what has been a turbulent year. They are all included on the Goldman Sachs Conviction List too.
Published:
Wednesday's top analyst upgrades and downgrades included Alphabet, Advanced Micro Devices, Corning, FireEye, Inovia Pharmaceuticals, Lululemon Athletica, Nike, Roku, Starbucks, Tyson Foods and...
Published:
The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Published: